← Leaderboards
Miriam Cremer
Cleveland Clinic Lerner Com-Cwru
$10,752,634
Attributed
$11,832,121
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.2M · FY2014–25$2.5M$1.9M$1.3M$625K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,832,121 · 6
By mechanism
R01$6,009,972 · 2
UH3$2,799,267 · 1
R44$1,997,669 · 1
UH2$985,213 · 1
R13$40,000 · 1
Top collaborators
- Youxiang Wang2 shared
- Karla Alfaro1 shared
Most similar at Cleveland Clinic Lerner Com-Cwru
Same institution · by research overlap
- Karla Alfaro$625,660
- Montserrat Soler$202,487
Others in their field
Top investigators on “Human Papillomavirus”
- Ronald T Mitsuyasu · University Of California Los Angeles$106,431,894
- Leonard Freedman · Leidos Biomedical Research, Inc.$53,948,093
- Kathryn M Anastos · Montefiore Medical Center (Bronx, Ny)$50,130,116
- Paula Gonzalez-Maya · Fundacion Inciensa$38,145,031
- David Heimbrook · Leidos Biomedical Research, Inc.$33,306,253
- Paul F Lambert · University Of Wisconsin Madison$31,091,618
Research focus
Human PapillomavirusLow And Middle-Income CountriesScreeningWomanTechnologyDetectionCervicalMalignant Neoplasm Of Cervix UteriProgramsMortalityPremalignantWorld Health OrganizationLesionCervical Intraepithelial NeoplasiaPortabilityAreaEvaluationCervical Cancer PreventionCervical Cancer ScreeningCost EffectivenessGuidelinesRunningInnovationCountry
Grant awards (22)
Single Visit Clinical Validation of ScreenFire, a Low-Cost HPV Test: Efficacy and Cost Effectiveness (SCALE)$531,062
R01 · FY2025 · CA · contact PI
Single Visit Clinical Validation of ScreenFire, a Low-Cost HPV Test: Efficacy and Cost Effectiveness (SCALE)$503,441
R01 · FY2024 · CA · contact PI
PROGRESS: PRevention of cervical cancer using the Genotyping scREening and Same-day Self-sampling$986,359
R44 · FY2023 · CA
Single Visit Clinical Validation of ScreenFire, a Low-Cost HPV Test: Efficacy and Cost Effectiveness (SCALE)$522,121
R01 · FY2023 · CA · contact PI
Comparison of cervical intraepithelial neoplasia 2/3 treatment outcomes with a portable LMIC-adapted thermal ablation device vs. gas-based cryotherapy$490,168
R01 · FY2023 · CA · contact PI
Development of an HPV stigma assessment scale and a stigma-reducing intervention to improve cervical cancer prevention in El Salvador$180,289
R01 · FY2023 · CA · contact PI
PROGRESS: PRevention of cervical cancer using the Genotyping scREening and Same-day Self-sampling$1,011,310
R44 · FY2022 · CA
Comparison of cervical intraepithelial neoplasia 2/3 treatment outcomes with a portable LMIC-adapted thermal ablation device vs. gas-based cryotherapy$631,938
R01 · FY2022 · CA · contact PI
Single Visit Clinical Validation of ScreenFire, a Low-Cost HPV Test: Efficacy and Cost Effectiveness (SCALE)$578,801
R01 · FY2022 · CA · contact PI
Comparison of cervical intraepithelial neoplasia 2/3 treatment outcomes with a portable LMIC-adapted thermal ablation device vs. gas-based cryotherapy$183,207
R01 · FY2021 · CA · contact PI
TeleMed: Comparison of cervical intraepithelial neoplasia 2/3 treatment outcomes with a portable LMIC-adapted thermal ablation device vs. gas-based cryotherapy$161,305
R01 · FY2021 · CA · contact PI
Comparison of cervical intraepithelial neoplasia 2/3 treatment outcomes with a portable LMIC-adapted thermal ablation device vs. gas-based cryotherapy$106,956
R01 · FY2021 · CA · contact PI
Comparison of cervical intraepithelial neoplasia 2/3 treatment outcomes with a portable LMIC-adapted thermal ablation device vs. gas-based cryotherapy$897,307
R01 · FY2020 · CA · contact PI
1st International Symposium of Resource-Appropriate Technologies for Global Oncology$40,000
R13 · FY2020 · CA · contact PI
Comparison of cervical intraepithelial neoplasia 2/3 treatment outcomes with a portable LMIC-adapted thermal ablation device vs. gas-based cryotherapy$485,022
R01 · FY2019 · CA · contact PI
Development of an LMIC-adapted Thermocoagulation Prototype for the Treatment of Cervical Pre-cancer.$69,146
R01 · FY2019 · CA · contact PI
CryoPen: An Innovative Treatment for Cervical Precancer in Low-Resource Setting$903,427
UH3 · FY2018 · CA · contact PI
Comparison of cervical intraepithelial neoplasia 2/3 treatment outcomes with a portable LMIC-adapted thermal ablation device vs. gas-based cryotherapy$669,209
R01 · FY2018 · CA · contact PI
CryoPen: An Innovative Treatment for Cervical Precancer in Low-Resource Setting$936,421
UH3 · FY2017 · CA · contact PI
CryoPen: An Innovative Treatment for Cervical Precancer in Low-Resource Setting$959,419
UH3 · FY2016 · CA · contact PI
CryoPen: An Innovative Treatment for Cervical Precancer in Low-Resource Setting$487,180
UH2 · FY2015 · CA · contact PI
CryoPen: An Innovative Treatment for Cervical Precancer in Low-Resource Setting$498,033
UH2 · FY2014 · CA · contact PI